Another Early Win for TAVI in Low-Risk Patients

Transcatheter aortic-valve implantation (TAVI) has become the dominant, if not default, therapy for patients with severe, symptomatic aortic stenosis who are at intermediate, high, or prohibitive risk for surgical aortic-valve replacement (SAVR). Several randomized trials have shown that TAVI in patients at low surgical risk is either noninferior or superior in safety and efficacy as compared with SAVR at 1 to 2 years. 1-3 Moreover, longer-term clinical outcomes of TAVI as compared with SAVR in such patients have held up at 4 years in the Evolut Low Risk trial, 4 5 years in the PARTNER 3 trial, 5 and 10 years in the . . .